Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
Elena Makino(University of Tübingen), Birgit Schittek(Hertie Institute for Clinical Brain Research)
Cited by 29
Related Papers
β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance
|PLoS ONE|2011|108
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
|Oncotarget|2017|48
Histological and functional characterization of 3D human skin models mimicking the inflammatory skin diseases psoriasis and atopic dermatitis
|Disease Models & Mechanisms|2024|18
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>
|Cancer Research Communications|2023|15
<scp>PARP1</scp> expression predicts <scp>PARP</scp> inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma
|International Journal of Cancer|2024|12